OBJECTIVE: Ferumoxytol, an ultrasmall superparamagnetic iron oxide particle, has been suggested as a potential alternative MRI contrast agent in patients with renal failure. We compared ferumoxytol to gadoteridol enhancement on T1- and T2-weighted MRI in CNS disorders to explore its diagnostic utility. SUBJECTS AND METHODS: Data were collected from three protocols in 70 adults who underwent alternate-day gadoteridol- and ferumoxytol-enhanced MRI using identical parameters. Two neuroradiologists measured lesion-enhancing size and intensity on contrast-enhanced T1-weighted images in consensus. T2-weighted images were evaluated for the presence of contrast-enhanced hypointensity. Mixed model repeated measures analysis of variance determined differences between T1-weighted enhancement size and intensity for individual protocols and group. RESULTS: After exclusions, 49 MRI studies in 29 men and 20 women (mean age, 51 years) were assessed. T1-weighted estimated enhancing sizes were different between agents (p = 0.0456) as a group; however, no differences were observed with untreated gliomas (n = 17) in two protocols (p = 1.0 and p = 0.99, respectively). Differences in T1-weighted enhancement intensity between agents were significant for the group overall (p = 0.0006); however, three-way interactions were not significant (p = 0.1233). T2-weighted images were assessed for contrast-enhanced hypointensity, observed in 26 of 49 (53%) ferumoxytol and zero of 49 (0%) gadoteridol scans. CONCLUSION: Ferumoxytol may be a useful MRI contrast agent in patients who are unable to receive gadolinium-based contrast agents. Greater experience with a wider variety of disorders is necessary to understand differences in enhancement with ferumoxytol compared with gadolinium-based contrast agents, given their different mechanisms of action.
OBJECTIVE:Ferumoxytol, an ultrasmall superparamagnetic iron oxide particle, has been suggested as a potential alternative MRI contrast agent in patients with renal failure. We compared ferumoxytol to gadoteridol enhancement on T1- and T2-weighted MRI in CNS disorders to explore its diagnostic utility. SUBJECTS AND METHODS: Data were collected from three protocols in 70 adults who underwent alternate-day gadoteridol- and ferumoxytol-enhanced MRI using identical parameters. Two neuroradiologists measured lesion-enhancing size and intensity on contrast-enhanced T1-weighted images in consensus. T2-weighted images were evaluated for the presence of contrast-enhanced hypointensity. Mixed model repeated measures analysis of variance determined differences between T1-weighted enhancement size and intensity for individual protocols and group. RESULTS: After exclusions, 49 MRI studies in 29 men and 20 women (mean age, 51 years) were assessed. T1-weighted estimated enhancing sizes were different between agents (p = 0.0456) as a group; however, no differences were observed with untreated gliomas (n = 17) in two protocols (p = 1.0 and p = 0.99, respectively). Differences in T1-weighted enhancement intensity between agents were significant for the group overall (p = 0.0006); however, three-way interactions were not significant (p = 0.1233). T2-weighted images were assessed for contrast-enhanced hypointensity, observed in 26 of 49 (53%) ferumoxytol and zero of 49 (0%) gadoteridol scans. CONCLUSION:Ferumoxytol may be a useful MRI contrast agent in patients who are unable to receive gadolinium-based contrast agents. Greater experience with a wider variety of disorders is necessary to understand differences in enhancement with ferumoxytol compared with gadolinium-based contrast agents, given their different mechanisms of action.
Authors: L L Muldoon; P G Tratnyek; P M Jacobs; N D Doolittle; G A Christoforidis; J A Frank; M Lindau; P R Lockman; S P Manninger; Y Qiang; A M Spence; S I Stupp; M Zhang; E A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2006-03 Impact factor: 3.825
Authors: Edit Dósa; Daniel J Guillaume; Marianne Haluska; Cynthia A Lacy; Bronwyn E Hamilton; Jeffrey M Njus; William D Rooney; Dale F Kraemer; Leslie L Muldoon; Edward A Neuwelt Journal: Neuro Oncol Date: 2010-12-16 Impact factor: 12.300
Authors: Peter Varallyay; Gary Nesbit; Leslie L Muldoon; Randal R Nixon; Johnny Delashaw; James I Cohen; Annie Petrillo; Doris Rink; Edward A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2002-04 Impact factor: 3.825
Authors: Philippe Bourrinet; Howard H Bengele; Bruno Bonnemain; Anne Dencausse; Jean-Marc Idee; Paula M Jacobs; Jerome M Lewis Journal: Invest Radiol Date: 2006-03 Impact factor: 6.016
Authors: Edward A Neuwelt; Bronwyn E Hamilton; Csanad G Varallyay; William R Rooney; Robert D Edelman; Paula M Jacobs; Suzanne G Watnick Journal: Kidney Int Date: 2008-10-08 Impact factor: 10.612
Authors: Edward A Neuwelt; Csanád G Várallyay; Sándor Manninger; Diána Solymosi; Marianne Haluska; Matthew A Hunt; Gary Nesbit; Alexander Stevens; Michael Jerosch-Herold; Paula M Jacobs; John M Hoffman Journal: Neurosurgery Date: 2007-04 Impact factor: 4.654
Authors: Jawad Fares; Deepak Kanojia; Aida Rashidi; Atique U Ahmed; Irina V Balyasnikova; Maciej S Lesniak Journal: Clin Breast Cancer Date: 2019-06-05 Impact factor: 3.225
Authors: Csanad G Varallyay; Eric Nesbit; Rongwei Fu; Seymur Gahramanov; Brendan Moloney; Eric Earl; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt Journal: J Cereb Blood Flow Metab Date: 2013-03-13 Impact factor: 6.200
Authors: Andrea Horváth; Csanad G Varallyay; Daniel Schwartz; Gerda B Toth; Joao P Netto; Ramon Barajas; Péter Várallyay; László Szidonya; Jenny Firkins; Emily Youngers; Rongwei Fu; Prakash Ambady; Péter Bogner; Edward A Neuwelt Journal: Magn Reson Med Date: 2017-12-04 Impact factor: 4.668
Authors: Joseph B Mandeville; Christina H Liu; Wim Vanduffel; John J A Marota; Bruce G Jenkins Journal: Neuropharmacology Date: 2014-03-05 Impact factor: 5.250
Authors: Bruce A Bowser; Norbert G Campeau; Carrie M Carr; Felix E Diehn; Jennifer S McDonald; Gary M Miller; Timothy J Kaufmann Journal: Neuroradiology Date: 2016-10-04 Impact factor: 2.804
Authors: Gerda B Toth; Csanad G Varallyay; Andrea Horvath; Mustafa R Bashir; Peter L Choyke; Heike E Daldrup-Link; Edit Dosa; John Paul Finn; Seymur Gahramanov; Mukesh Harisinghani; Iain Macdougall; Alexander Neuwelt; Shreyas S Vasanawala; Prakash Ambady; Ramon Barajas; Justin S Cetas; Jeremy Ciporen; Thomas J DeLoughery; Nancy D Doolittle; Rongwei Fu; John Grinstead; Alexander R Guimaraes; Bronwyn E Hamilton; Xin Li; Heather L McConnell; Leslie L Muldoon; Gary Nesbit; Joao P Netto; David Petterson; William D Rooney; Daniel Schwartz; Laszlo Szidonya; Edward A Neuwelt Journal: Kidney Int Date: 2017-04-20 Impact factor: 10.612
Authors: Hushan Yuan; Moses Q Wilks; Marc D Normandin; Georges El Fakhri; Charalambos Kaittanis; Lee Josephson Journal: Nat Protoc Date: 2018-01-25 Impact factor: 13.491
Authors: Brian T Farrell; Bronwyn E Hamilton; Edit Dósa; Endre Rimely; Morad Nasseri; Seymur Gahramanov; Cynthia A Lacy; Eugene P Frenkel; Nancy D Doolittle; Paula M Jacobs; Edward A Neuwelt Journal: Neurology Date: 2013-06-14 Impact factor: 9.910